SCHEMBL23877580

SCHEMBL23877580

COC(=O)c1ccc(S(F)(F)(F)(F)F)cc1N

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.60
▸ KDM4E B2RXH2 7/20 0.60
▸ GAA P10253 6/20 0.60
▸ MAPT P10636 4/20 0.60
▸ HPGD P15428 4/20 0.60
▸ HSD17B10 Q99714 3/20 0.60
▸ GLA P06280 2/20 0.60
▸ CASP1 P29466 1/20 0.60
▸ CASP7 P55210 1/20 0.60
▸ ATM Q13315 1/20 0.60
▸ ABL1 P00519 1/20 0.58
▸ CFTR P13569 5/20 0.58
▸ TSHR P16473 2/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ CA12 O43570 2/20 0.42
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CA7 P43166 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ CA14 Q9ULX7 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1194676 0.81 HSD17B1 (0.38) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL2342509 0.80 ABL1 (0.46) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL29377565 0.79 ALDH1A1 (0.53) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL1194182 0.79 ALDH1A1 (0.53) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL1194900 0.78 KDM4E (0.36) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL1635223 0.78 ABL1 (0.47) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL1035480 0.77 ALDH1A1 (0.66) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL2926607 0.77 GAA (0.70) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL29400478 0.77 GAA (0.70) ALDH1A1KDM4EGAAMAPTHPGD
SCHEMBL2387646 0.76 ALDH1A1 (0.64) ALDH1A1KDM4EGAAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 — — EP disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 — — US disclosed
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives THE LIVER COMPANY INC. (US) 2021-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B ALDH1A1 245/4885KDM4E 3158/4885GAA 838/4885
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B ALDH1A1 245/4885KDM4E 3158/4885GAA 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback